CHICMAX (02145) Signs Exclusive Strategic Framework with Suzhou Kintor to Fast-Track Commercialisation of Whitening Ingredient “KT-939”

Shanghai Chicmax Cosmetic Co., Ltd. (CHICMAX, 02145) has entered into a strategic cooperation framework agreement with Suzhou Kintor Pharmaceutical Inc., a wholly-owned subsidiary of Kintor Pharmaceutical Limited (09939). The partnership grants CHICMAX exclusive rights in the cosmetics field to accelerate registration and commercialisation of KT-939, a novel whitening and freckle-removing ingredient.

Under the framework, both parties will collaborate on: 1. Registration of KT-939 as a new cosmetic ingredient in China. 2. Registration and development of cosmetic products featuring KT-939 as the core functional component. 3. Joint R&D and customisation aimed at positioning KT-939 as a leading domestic whitening agent.

CHICMAX will leverage its multi-brand consumer insight and market execution capabilities, while Suzhou Kintor contributes drug-discovery expertise and technological resources. The alliance targets simultaneous market launches of the ingredient and finished products, alongside cooperation in technology sharing, IP protection and promotion.

Management believes the agreement will enhance CHICMAX’s product diversification and reinforce its competitive moat in whitening and freckle-removal segments. All KT-939 materials and related products remain subject to final regulatory approval; timelines and outcomes are uncertain, and the company will update the market on subsequent developments.

The transaction is conducted on normal commercial terms, and Suzhou Kintor and its ultimate owners are independent of CHICMAX and its connected persons. Shareholders and potential investors are advised to exercise caution when dealing in CHICMAX securities.